GLP-1 receptor agonists as potential disease-modifying agents in Parkinson's and Alzheimer's disease: mechanisms, clinical trial evidence, and the neuroprotection horizon.
This newly indexed research record examines “GLP-1 receptor agonists as potential disease-modifying agents in Parkinson's and Alzheimer's disease: mechanisms, clinical trial evidence, and the neuroprotection horizon.” Use the linked PubMed (NCBI) publication to assess the study design, population, methods, findings and limitations; an indexed record alone should not be read as clinical guidance.
Open original source ↗Collected Nov 8, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.